MK-2870-101 - Clinical trial • Breast Cancer Foundation NZ

MK-2870-101

Advanced Breast Cancer clinical trials for ER+

Recruiting
Updated: September 13, 2025

An open-label randomised Phase 3 study of MK-2870 by itself and in combination with Keytruda (pembrolizumab) versus a treatment of physician's choice in participants with HR+/HER2- unresectable, locally advanced or metastatic breast cancer.

The drug, MK-2870, is also known as sacituzumab tirumotecan.

Criteria

- Unresectable locally advanced or metastatic HR+/HER2- breast cancer.

- Disease recurrence on/after receiving a CDK4/6 inhibitor (eg palbociclib, ribociclib, abemaciclib).

- Patients who have had chemotherapy in metastatic setting are not eligible. 

- Patients who have had disease recurrence within 6 months of completing adjuvant or neoadjuvant chemotherapy are not eligible. 

More comprehensive info

New Zealand

Auckland

Australia



If you think you might be a candidate for this trial, use the contact details supplied, or talk to your doctor.

Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at intouch@bcf.org.nz

Similar clinical trials

For Advanced Breast Cancer

  • BGB-43395-101
    Updated: September 8, 2025
    Recruiting
    New Zealand & Australia
    This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works alone or in combination with fulvestrant, letrozole, or elacestrant in patients with advanced HR+/HER2- breast cancer (BC). The main purpose of this study is to explore the recommended dosing for BGB-43395.
    More details

  • MK-2870-011/​TroFuse-011
    Updated: September 8, 2025
    Recruiting
    New Zealand
    Researchers want to know if MK-2870 given by itself or with Keytruda (pembrolizumab) can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with MK-2870 alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.
    More details

  • pionERA Trial
    Updated: September 5, 2025
    Recruiting
    New Zealand & Australia
    This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with a CDK4/6 inhibitor (either palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy.
    More details

Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to intouch@bcf.org.nz

Find clinical trials

Interested in a clinical trial?

Subscribe for updates & stay in the loop with new studies.